文献速递淋巴瘤造血干细胞移植与细胞治疗

CD19 CAR-T细胞免疫治疗在滤泡性淋巴瘤中实现高比例持久完全缓解

High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy.
PubMed 文献 · Blood · 2019-01-01

该1/2期临床试验纳入21例复发/难治性滤泡性淋巴瘤(FL,n=8)及组织学转化FL(tFL,n=13)患者,采用环磷酰胺联合氟达拉滨淋巴清除后输注2×10^6/kg CD19 CAR-T细胞。FL患者完全缓解率达88%,tFL为46%;FL达完全缓解者在中位随访24个月时均维持缓解。

要点

  • CD19 CAR-T在复发/难治FL中完全缓解率达88%,tFL为46%。
  • FL达完全缓解患者中位随访24个月均维持缓解。
  • tFL中位缓解持续时间10.2个月,中位随访38个月。

核心结论

  • CD19 CAR-T细胞免疫治疗对伴或不伴组织学转化的临床侵袭性复发/难治FL成人患者高度有效,高比例FL患者获持久缓解。

研究设计与样本

  • 1/2期临床试验纳入21例复发/难治FL(n=8)及tFL(n=13)患者,采用环磷酰胺联合氟达拉滨淋巴清除后输注2×10^6/kg CD19 CAR-T细胞。
  • 试验注册号NCT01865617。

主要发现

  • 按Lugano标准,FL患者完全缓解率为88%,tFL患者为46%。
  • FL达完全缓解患者在中位随访24个月时均维持缓解。
  • tFL患者中位缓解持续时间为10.2个月,中位随访38个月。
  • FL与tFL患者细胞因子释放综合征发生率分别为50%和39%,神经毒性分别为50%和23%,无≥3级严重不良事件。
  • FL与tFL患者CAR-T细胞体内扩增/持久性无显著差异。

关键数值与推荐

  • 完全缓解按Lugano标准评估。
  • 淋巴清除方案为环磷酰胺联合氟达拉滨,CAR-T输注剂量为2×10^6/kg。

临床怎么用

  • CD19 CAR-T可用于伴或不伴组织学转化的复发/难治FL成人患者,FL患者完全缓解率高且持久。

局限性

  • 样本量小(共21例),FL仅8例,tFL 13例。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with follicular lymphoma (FL) with early relapse after initial chemoimmunotherapy, refractory disease, or histologic transformation (tFL) have limited progression-free and overall survival. We report efficacy and long-term follow-up of 21 patients with relapsed/refractory (R/R) FL (n = 8) and tFL (n = 13) treated on a phase 1/2 clinical trial with cyclophosphamide and fludarabine lymphodepletion followed by infusion of 2 × 106 CD19-directed chimeric antigen receptor-modified T (CAR-T) cells per kilogram. The complete remission (CR) rates by the Lugano criteria were 88% and 46% for patients with FL and tFL, respectively. All patients with FL who achieved CR remained in remission at a median follow-up of 24 months. The median duration of response for patients with tFL was 10.2 months at a median follow-up of 38 months. Cytokine release syndrome occurred in 50% and 39%, and neurotoxicity in 50% and 23% of patients with FL and tFL, respectively, with no severe adverse events (grade ≥3). No significant differences in CAR-T cell in vivo expansion/persistence were observed between FL and tFL patients. CD19 CAR-T cell immunotherapy is highly effective in adults with clinically aggressive R/R FL with or without transformation, with durable remission in a high proportion of FL patients. This trial was registered at clinicaltrials.gov as #NCT01865617.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Hirayama AV, Gauthier J, Hay KA, et al. High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. Blood. 2019. PMID: 31648294. doi:10.1182/blood.2019000905

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。